New drug combo aims to shrink Hard-to-Treat salivary gland tumors
NCT ID NCT04895735
First seen Feb 02, 2026 · Last updated May 12, 2026 · Updated 14 times
Summary
This study tests whether combining the chemotherapy drug pemetrexed with the immunotherapy drug pembrolizumab can shrink or control advanced salivary gland cancer that has returned or spread. About 45 adults with this rare cancer will receive both drugs intravenously. The goal is to see how many patients benefit, either by tumor shrinkage or disease stabilization.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.